GlassScriptPhysician profile
Ralph D Ensley
NPI 1225082795
$11,141.62
in general payments reported to CMS, 2019-2025
31 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $291 · 2021: $604 · 2022: $590 · 2023: $3,296 · 2024: $3,426 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,941 · Travel and Lodging: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,941.21 |
| Travel and Lodging | $2,351.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,485.99 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Respicardia, INC. | $1,949.82 | 2023 | Remede System |
| Abiomed | $1,928.19 | 2020-2025 | Impella |
| Boston Scientific Corporation | $918.06 | 2019-2025 | Watchman Flx, Peripheral Rotalink Plus, Ekosonic |
| Heartflow, INC. | $702.36 | 2022-2024 | Ffrct |
| Acist Medical Systems, INC. | $645.43 | 2019-2021 | |
| Cook Medical LLC | $517.64 | 2019 | |
| Impulse Dynamics (USA) INC. | $317.01 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $266.04 | 2019-2023 | Sapien 3 Ultra Resilia |
| Amgen INC. | $183.34 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $169.26 | 2021-2025 | |
| Medtronic Vascular, INC. | $165.28 | 2019-2020 | |
| Inari Medical, INC. | $94.37 | 2020-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cvrx, INC. | $81.46 | 2024 | Barostim Neo System |
| Pfizer INC. | $81.37 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $75.38 | 2021-2024 | Resolute Onyx |
| Cardiac Dimensions, INC. | $71.93 | 2024-2025 | |
| Daiichi Sankyo INC. | $62.20 | 2025 | Injectafer |
| Angiodynamics, INC. | $59.34 | 2021-2025 | Alphavac |
| Sensible Medical Innovations INC | $55.80 | 2025 | Reds System |
| Silk Road Medical, INC. | $52.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.47 | 2022-2025 | Eliquis |
| Vivaquant INC, Dba Rhythm Express | $41.80 | 2024 | Rhythm Express |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.57 | 2022-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $25.02 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.14 | 2024 | |
| Novo Nordisk INC | $17.26 | 2024 | Rybelsus, Ozempic |
| Philips North America LLC | $17.13 | 2024 | (Ck4) Mcot |
| Shockwave Medical, INC | $16.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.55 | 2023 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.62 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Ensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.